Literature DB >> 9427231

Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis.

B M Koffman1, M Rugiero, M C Dalakas.   

Abstract

We reviewed 99 patients with sporadic inclusion body myositis (IBM), searching for a coexisting autoimmune disease, other conditions with altered immune function, or the presence of autoantibodies. Thirteen patients had one or more of 11 diseases with altered immune function. Forty-three patients had elevated titers of one or more of nine different, albeit nondisease-specific, autoantibodies. Twenty-five patients had dysproteinemia or dysproteinuria. We conclude that IBM is frequently associated with systemic immune disorders or nonspecific autoantibodies. Although aging may explain some of these phenomena, an altered immune function need to be considered in the pathogenesis of IBM.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9427231     DOI: 10.1002/(sici)1097-4598(199801)21:1<115::aid-mus15>3.0.co;2-2

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  13 in total

1.  Intravenous immunoglobulin in patients with anti-GAD antibody-associated neurological diseases and patients with inflammatory myopathies: effects on clinicopathological features and immunoregulatory genes.

Authors:  Marinos C Dalakas
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

2.  [PM-Scl antibody positive systemic sclerosis associated with inclusion-body myositis].

Authors:  S Kim; E Genth; T Krieg; N Hunzelmann
Journal:  Z Rheumatol       Date:  2005-10       Impact factor: 1.372

Review 3.  Autoimmune Myopathies: Updates on Evaluation and Treatment.

Authors:  Emer R McGrath; Christopher T Doughty; Anthony A Amato
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

Review 4.  Idiopathic inflammatory myopathy: autoantibody update.

Authors:  Ira N Targoff
Journal:  Curr Rheumatol Rep       Date:  2002-10       Impact factor: 4.592

Review 5.  Differential diagnosis of idiopathic inflammatory myopathies.

Authors:  Alan N Baer
Journal:  Curr Rheumatol Rep       Date:  2006-06       Impact factor: 4.686

6.  Autoantibodies against a 43 KDa muscle protein in inclusion body myositis.

Authors:  Mohammad Salajegheh; Theresa Lam; Steven A Greenberg
Journal:  PLoS One       Date:  2011-05-23       Impact factor: 3.240

7.  Epidemiology and Natural History of Inclusion Body Myositis: A 40-Year Population-Based Study.

Authors:  Shahar Shelly; Michelle M Mielke; Jay Mandrekar; Margherita Milone; Floranne C Ernste; Elie Naddaf; Teerin Liewluck
Journal:  Neurology       Date:  2021-04-20       Impact factor: 11.800

8.  Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis.

Authors:  Marinos C Dalakas; Goran Rakocevic; Jens Schmidt; Mohammad Salajegheh; Beverly McElroy; Michael O Harris-Love; Joseph A Shrader; Ellen W Levy; James Dambrosia; Robert L Kampen; David A Bruno; Allan D Kirk
Journal:  Brain       Date:  2009-05-19       Impact factor: 13.501

9.  Autoantibodies produced at the site of tissue damage provide evidence of humoral autoimmunity in inclusion body myositis.

Authors:  Arundhati Ray; Anthony A Amato; Elizabeth M Bradshaw; Kevin J Felice; Daniel B DiCapua; Jonathan M Goldstein; Ingrid E Lundberg; Richard J Nowak; Hidde L Ploegh; Eric Spooner; Qian Wu; Simon N Willis; Kevin C O'Connor
Journal:  PLoS One       Date:  2012-10-05       Impact factor: 3.240

Review 10.  Neurology of rheumatologic disorders.

Authors:  Amre Nouh; Olimpia Carbunar; Sean Ruland
Journal:  Curr Neurol Neurosci Rep       Date:  2014-07       Impact factor: 6.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.